ESPR vs ZOM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a StrongBuy and ZOM is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ESPR’s FA Score shows that 1 FA rating(s) are green whileZOM’s FA Score has 1 green FA rating(s).
- ESPR’s FA Score: 1 green, 4 red.
- ZOM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ESPR’s TA Score shows that 5 TA indicator(s) are bullish while ZOM’s TA Score has 5 bullish TA indicator(s).
- ESPR’s TA Score: 5 bullish, 4 bearish.
- ZOM’s TA Score: 5 bullish, 5 bearish.
Price Growth
ESPR (@Pharmaceuticals: Other) experienced а +15.76% price change this week, while ZOM (@Medical Specialties) price change was +4.18% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.90%. For the same industry, the average monthly price growth was +0.03%, and the average quarterly price growth was +37.26%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.76%. For the same industry, the average monthly price growth was +7.52%, and the average quarterly price growth was +0.65%.
Reported Earning Dates
ESPR is expected to report earnings on Nov 05, 2024.
ZOM is expected to report earnings on Nov 11, 2024.
Industries' Descriptions
@Pharmaceuticals: Other (+0.90% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+5.76% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ESPR | ZOM | ESPR / ZOM | |
| Capitalization | 496M | 137M | 362% |
| EBITDA | -150.11M | -11.94M | 1,258% |
| Gain YTD | -36.120 | -34.016 | 106% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 116M | 24M | 483% |
| Total Cash | 82.2M | 106M | 78% |
| Total Debt | 266M | 1.75M | 15,183% |
ESPR | ZOM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 95 | |
PRICE GROWTH RATING 1..100 | 60 | 80 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZOM's Valuation (29) in the Pharmaceuticals Major industry is in the same range as ESPR (31) in the Biotechnology industry. This means that ZOM’s stock grew similarly to ESPR’s over the last 12 months.
ZOM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ZOM’s stock grew similarly to ESPR’s over the last 12 months.
ZOM's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ZOM’s stock grew similarly to ESPR’s over the last 12 months.
ESPR's Price Growth Rating (60) in the Biotechnology industry is in the same range as ZOM (80) in the Pharmaceuticals Major industry. This means that ESPR’s stock grew similarly to ZOM’s over the last 12 months.
ESPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ZOM (100) in the Pharmaceuticals Major industry. This means that ESPR’s stock grew similarly to ZOM’s over the last 12 months.
| ESPR | ZOM | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 78% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 87% | 4 days ago 88% |
| Momentum ODDS (%) | 4 days ago 87% | 4 days ago 78% |
| MACD ODDS (%) | 4 days ago 76% | 4 days ago 86% |
| TrendWeek ODDS (%) | 4 days ago 85% | 4 days ago 81% |
| TrendMonth ODDS (%) | 4 days ago 82% | 4 days ago 83% |
| Advances ODDS (%) | 4 days ago 86% | 5 days ago 84% |
| Declines ODDS (%) | 11 days ago 87% | 13 days ago 84% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 88% | 4 days ago 81% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| DCCRX | 27.48 | 0.63 | +2.35% |
| Delaware Small Cap Core R | |||
| EMSLX | 17.64 | 0.15 | +0.86% |
| Shelton Emerging Markets Investor | |||
| DRDCX | 26.22 | 0.15 | +0.58% |
| Dearborn Partners Rising Dividend C | |||
| GGEYX | 28.24 | 0.14 | +0.50% |
| GuideStone Funds Growth Equity Instl | |||
| GSTIX | 12.92 | 0.06 | +0.47% |
| Goldman Sachs Strategic Growth Instl | |||
ESPR and
Correlation & Price change
A.I.dvisor tells us that ESPR and PTPI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and PTPI's prices will move in lockstep.
| Ticker / NAME | Correlation To ESPR | 1D Price Change % | ||
|---|---|---|---|---|
| ESPR | 100% | +9.14% | ||
| PTPI - ESPR | 29% Poorly correlated | -0.84% | ||
| CTLT - ESPR | 29% Poorly correlated | -0.12% | ||
| ORGO - ESPR | 28% Poorly correlated | +7.66% | ||
| PAHC - ESPR | 26% Poorly correlated | +3.68% | ||
| ZOM - ESPR | 26% Poorly correlated | -0.30% | ||
More | ||||